Executive Team

Richard Bungay, BSc ACA - Interim Chief Executive Officer and Chief Financial Officer

Richard has over 25 years’ experience in senior finance and strategic roles within the pharmaceutical and biotechnology sector. His prior experience includes CFO and COO of Mereo BioPharma, CFO of Glide Technologies, CFO of Verona Pharma, CEO (formerly CFO) of Chroma Therapeutics, Director of Corporate Communications and Strategic Planning at Celltech and Finance Director of the Respiratory and Inflammation therapy area at AstraZeneca. Richard is also a Non-Executive Director of Cambridge Cognition Holdings plc and Chroma Therapeutics Limited. He qualified as a Chartered Accountant with Deloitte and has a first class degree in Chemistry from Nottingham University. ... Show more

Mike Scott, BSc, FCCA, CTA - Interim Chief Financial Officer

Mike Scott is Interim Chief Financial Officer at Diurnal. Mike joined the company as Group Financial Controller in 2020. Mike was formerly CFO at TrakCel, a provider of software solutions for advanced cell therapies. Prior to that held a number of senior finance positions including Global Finance Business Partner at PCI Pharma Services. Mike qualified in public practice in 2006 and is a fellow of the Association of Chartered Certified Accountants and a member of the Chartered Institute of Taxation. Mike has a degree in Accounting and Finance from Cardiff University.... Show more

Richard Ross, MBBS MD FRCP - Chief Scientific Officer

Richard is a founding Director of Diurnal. He is a Professor of Clinical Endocrinology and Head of the Academic Unit of Diabetes, Endocrinology and Metabolism at the University of Sheffield and was previously a Senior Lecturer at St. Bartholomew’s Hospital, London. Richard’s primary research interest is pituitary and adrenal disease with a particular focus on hormone replacement. His research has yielded over 200 papers, more than 30 granted patents and publications in Nature Medicine, Nature Reviews Endocrinology, Nature Genetics, The Lancet, The BMJ and PNAS. He has been a member of the editorial boards of Clinical Endocrinology and the Journal of Clinical Endocrinology and Metabolism and served as an elected member of the executive committees for the European Society of Endocrinology (Treasurer), the Society for Endocrinology, the Growth Hormone Research Society and the Pituitary Society. Richard is also a Director of Asterion Limited.... Show more

John Porter, MBBS PhD - Chief Medical Officer

John Porter is Chief Medical Officer at Diurnal. John is a paediatric endocrinologist and has 10 years’ experience in the pharmaceutical industry. Previously, John had medical director roles at Pfizer, Novartis and GSK covering a wide portfolio of medicines in therapy areas including endocrinology, haematology, infectious disease and vaccines. John studied medicine at Oxford and Newcastle-upon-Tyne Universities, qualifying in 1995. He trained in paediatric endocrinology and diabetes and has a PhD in the genetics of paediatric diabetes.... Show more

David Bevan, Chief Business Officer

David has over 30 years of pharmaceutical expertise with a broad base of general management, sales, marketing and commercial experience, in large and medium-sized pharmaceutical companies with Global, EU and UK responsibility. He has a wealth of successes and expertise in team leadership, transformation, change initiatives, commercialisation, ‘go to market’ models (including digitalisation), product launches, partnership, commercial excellence and capability building. Prior to working at Diurnal, David’s most recent roles were as CEO, ViforFresenius Medical Care Renal Pharma and Chief Marketing Officer, Vifor, in Zurich. ... Show more

Stewart Jones - Operations Director

Stewart has over 25 years’ experience in CMC and programme management, spanning the fine chemicals, CMO, Biotech and BioPharmaceutical industries. Stewart’s responsibility is to ensure that all of Diurnal’s development programmes are fully integrated and to manage their progress through to successful conclusion. Prior to joining Diurnal, Stewart was at AIM listed Mereo BioPharma as Head of CMC and oversaw all manufacturing activities. Before Mereo, Stewart was at Chroma Therapeutics for over 9 years and was responsible for the development of the clinical portfolio, all of which have been successfully licensed on. Previously Stewart worked in the development department at Evotec (now Aptuit) for 9 years leading teams on the manufacturing development of several different therapeutic entities from small molecules to large molecules, peptides and liquid crystals, some of which have subsequently gone on to commercial launch. Stewart has a BSc (hons) in chemistry.... Show more

Diurnal Limited (Company Number: 05237326) is registered in England & Wales. Registered office: Cardiff Medicentre, Heath Park, Cardiff CF14 4UJ, UK.